ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1279

Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Abstract Number: 2421

Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria
Abstract Number: 1487

Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
Abstract Number: 2154

Whole-Body MRI Findings in a Cohort of Children with Chronic Nonbacterial Osteomyelitis
Abstract Number: 0436

Why Do Patients with Rheumatic Disease Have MACE and Thrombotic Events?
Abstract Number: 1470

Why Do Some Lupus Patients Skip Their Mycophenolate Mofetil? A Multi-Factorial Assessment of Patient Compliance
Abstract Number: 0575

Why Do Some Psoriatic Arthritis Patients Fail Treatment? Exploring the Profile of D2T Patients
Abstract Number: 1612

Window of opportunity with tocilizumab therapy in giant cell arteritis. Multicenter study of 471 patients of clinical practice
Abstract Number: 0007

WITHDRAWN
Abstract Number: 2086

WOMAC Physical Function and 3D MRI Bone Shape: Advancing a “Virtual” Total Knee Replacement Endpoint for Knee Osteoarthritis Clinical Trials
Abstract Number: 2253

Wrist-worn Wearable Device Data Can Be a New Digital Biomarker For Disease Activity In Rheumatoid Arthritis: a Multicenter Single-arm Prospective Study
Abstract Number: 1698

X Chromosome DNA Methylation Changes Suggest Epigenetic Contributions to Immune Dysregulation in Male Lupus
Abstract Number: 0010

XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease
Abstract Number: 1155

Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial
Abstract Number: 0113

ZEB2 and MLCK1 may impair gut barrier integrity in MIF-Deficient SKG Mice

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].